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Until now, it remains unclear whether the addition of manual
daytime exchanges or increasing the nightly dialysate flow is
the best strategy to optimize automated peritoneal dialysis
(APD) treatment. In this open-label randomized controlled
crossover trial, 18 patients with high-average (HA) or
low-average (LA) peritoneal transport rates sequentially
underwent two different APD regimens for 7 days each, with
an intermittent washout period of 7 days. ‘Manual exchange’
treatment was a conventional APD with low nightly dialysate
flow and one manual daytime exchange. ‘High-flow’
treatment was defined by cycler therapy with high dialysate
flow but without manual daytime exchange. Creatinine
clearances (8.5671.22 vs 7.8771.04 l/treatment, P¼ 0.011)
and urea nitrogen clearances (12.8371.98 vs 11.6871.06 l/
treatment, P¼ 0.014) were significantly increased during
‘high-flow’ treatment compared to ‘manual exchange’
treatment. Sodium removal was significantly lower and
glucose absorption was higher with the ‘high-flow’ regimen.
Phosphate clearances, b2-microglobulin clearances,
ultrafiltration, and peritoneal protein loss were not different
between the two treatment modalities. Subgroup analysis
dependent on peritoneal transport types showed that the
effect on clearances was most marked and significant in HA
transporters, whereas sodium removal was lowest in LA
transporters. We conclude that small solute clearances can
be significantly improved and middle molecule clearances
maintained in APD patients by increasing the nightly
dialysate flow instead of adding a manual daytime exchange.
However, the possible benefit of better clearances with
higher nightly treatment volumes has to be weighed against
increased costs and the possible negative impact of impaired
sodium removal, especially in LA transporters.
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Automated peritoneal dialysis (APD) is a favorable option to
improve peritoneal clearances. However, a continuous APD
treatment (peritoneal cavity filled with dialysate between cycler
sessions, with or without manual exchanges) rather than
intermittent cycler therapy (peritoneal cavity empty between
treatments) is preferred in these patients. Usually in patients
on continuous cyclic peritoneal dialysis, a rather low dialysate
flow of 0.8–1.2 l/h is used to optimize clearances, correspond-
ing to nightly dialysate treatment volumes of 7–12 l during a
8–10 h cycler session.1,2 However, when using a low cycler
treatment volume, manual daytime exchanges are often
required to achieve adequate clearances, at least for patients
with low residual renal function.2 It should be considered that
manual daytime exchanges impair quality of life and may also
increase the risk of peritonitis. Furthermore, the question has
been raised whether the recommended low dialysate volumes
indeed maximally utilize the treatment options of APD. There
is evidence in the literature that increases of dialysate flow up
to 2 and 3 l/h improve small solute clearances as compared to
lower treatment volumes.3,4 To date, no study has opposed
such newer APD treatment options to the classical strategy of
optimizing dwell times with a lesser number of cycles and two
daytime dwells. Furthermore, most recent studies have focused
on removal of small solutes. However, when increasing the
nightly dialysate flow, clearances of larger uremic toxins and
sodium removal may be impaired.
In the present randomized controlled crossover trial, we
investigated whether a cycler therapy (tidal peritoneal
dialysis) with high dialysate flow during night time and
one daytime dwell (using icodextrin) provides at least similar
small solute clearances, middle molecule clearances, sodium
removal, peritoneal ultrafiltration, and protein loss as
compared to a conventional APD treatment with low
dialysate flow and one manual daytime exchange (one
daytime dwell with icodextrin, followed by one daytime
dwell with glucose solution) (Figure 1).
RESULTS
Patient characteristics and flow of participants
Of the 49 APD patients screened for inclusion in the study,
22 were randomized (Figure 2). There were four dropouts
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during the study period. One patient received a kidney graft
on the first day of treatment (‘high-flow’ treatment), and one
patient declined to continue the study on day 3 (‘manual
exchange’ treatment) without giving reasons for this decision.
One patient was withdrawn on day 4 (‘high-flow’ treatment)
because of dehydration and hypotension owing to massive
diarrhea, which occurred in combination with the contin-
uous ultrafiltration. The reason for dropout in the fourth
patient (day 3, ‘manual exchange’ treatment) was intolerable
abdominal distension. This latter patient had performed
nightly intermittent peritoneal dialysis before the start of the
study. Therefore, 18 APD patients were included in the final
analysis (Figure 2). The baseline demographic and clinical
characteristics of these patients are shown in Table 1. Causes
for end-stage renal disease were chronic glomerulonephritis
(n¼ 5), chronic kidney failure of unknown origin (n¼ 4),
chronic interstitial nephritis (n¼ 2), polycystic kidney disease
(n¼ 2), and miscellaneous diseases (n¼ 5). Although
diabetes was not an exclusion criterion, no diabetic patient
was included in this study.
Comparison of end points between the two treatments in the
whole-patient group
Primary end points. The average creatinine clearances
were 7.8771.04 l/treatment for ‘manual exchange’ treatment
compared to 8.5671.22 l/treatment for ‘high-flow’ treatment
(P¼ 0.011), demonstrating a significantly increased creati-
nine clearance when elevating the dialysate flow (Table 2).
Average urea nitrogen clearances were 11.6871.06 l/treat-
ment compared to 12.8371.98 l/treatment for the ‘manual
exchange’ and ‘high-flow’ regimens, respectively (P¼ 0.014).
Secondary end points. Phosphate and b2-microglobulin
clearances were not different between the two treatment
modalities. Peritoneal sodium removal was significantly less
with the ‘high-flow’ treatment as compared to ‘manual
exchange’ treatment (Table 2). In contrast, peritoneal
ultrafiltration and glucose absorption were slightly greater
with the ‘high-flow’ regimen (only significant for glucose
absorption). There was no difference in peritoneal protein
loss between both treatment modalities.
Subgroup analyses
Patients with body surface area 1.7–2 m2. Analyzing the
subgroup of patients with body surface area between 1.7 and
2 m2 (n¼ 12) yielded virtually identical results to those in the
entire study population. Creatinine clearances (P¼ 0.050)
and urea nitrogen clearances (P¼ 0.040) were significantly
increased after ‘high-flow’ treatment compared to ‘manual
exchange’ treatment. Sodium removal tended to decrease
(P¼ 0.064), whereas peritoneal ultrafiltration (P¼ 0.063)
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Figure 1 | Treatment regimens used in this randomized controlled crossover trial. BSA, body surface area; G, glucose; ICO, icodextrin;
L, liters.
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and glucose absorption (P¼ 0.081) tended to increase with
the ‘high-flow’ regimen. Phosphate clearance (P¼ 0.82),
b2-microglobulin clearance (P¼ 0.75), and protein loss
(P¼ 0.48) did not differ between the groups.
Comparison of end points within the subgroups of high-
average and low-average transporters. To account for differ-
ences between the two transport subtypes, we separately
analyzed patients categorized as high-average (HA) trans-
porter (dialysate to plasma ratio (D/P) of creatinine at
4 hX0.65, n¼ 8) or low-average (LA) transporter (D/P of
creatinine at 4 ho0.65, n¼ 10) with respect to the primary
and secondary study end points. In HA patients, we found
consistent results as in the entire cohort with significantly
higher creatinine clearances (9.3271.10 vs 8.2671.22 l/treat-
ment, P¼ 0.043) and urea nitrogen clearances (14.3871.45
vs 12.2570.78 l/treatment, P¼ 0.013) after ‘high-flow’
treatment as compared to ‘manual exchange’ treatment.
The difference in mean small solute clearances found in
HA transporters corresponds to an increase of creatinine
clearance of approximately 7 l/week when changing
from ‘manual exchange’ treatment to the ‘high-flow’ regi-
men. There were no significant differences in the other end
points between the two treatment modalities, except for a
higher peritoneal glucose absorption during ‘high-flow’ treat-
ment (227.6786.3 vs 170.9736.9 g/treatment, P¼ 0.022).
In LA patients, sodium removal was significantly lower
with the ‘high-flow’ regimen as compared to manual
exchange treatment (107.6767.4 vs 155.8794.3 mmol/treat-
ment, P¼ 0.009). We observed no significant differences in
primary end points (creatinine clearance, P¼ 0.15; urea
nitrogen clearance, P¼ 0.42) nor in any other secondary end
points. However, in seven of the 10 LA patients, peritoneal
creatinine and urea clearances increased when elevating the
dialysate flow (data not shown).
Cost analysis of treatments
As shown in Table 3, the ‘high-flow’ regimen was associated
with a 34–59% increase of costs as compared to ‘manual
exchange’ treatment.
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Figure 2 | Flow of participants and study design.
Table 1 | Demographic and clinical characteristics of the
18 APD patients included in the final analysis
Age (years)a 53.4714.4
Gender (female/male) 5/13
Duration of dialysis (months)a 15.078.8
Body surface area (m2)a 1.8570.18
Body surface area (o1.7/1.7–2/42 m2) 3/12/3
Body mass index (kg/m2)a 23.973.1
D/P creatinine at 4 ha 0.6570.09
Peritoneal transport type (HA/LA) 8/10
APD, automated peritoneal dialysis; D/P, dialysate to plasma ratio; HA, high-average
peritoneal transporters; LA, low-average peritoneal transporters.
aMean7s.d.
Table 2 | Comparison of peritoneal clearances, peritoneal protein loss, sodium removal, peritoneal ultrafiltration, and
peritoneal glucose absorption after two different APD treatment regimens, whole-patient group (n=18)
‘Manual exchange’ treatment ‘High flow’ treatment P-value
Primary end points
Creatinine clearance (l/treatment) 7.8771.04 8.5671.22 0.011
Urea nitrogen clearance (l/treatment) 11.6871.06 12.8371.98 0.014
Secondary end points
Phosphate clearance (l/treatment) 7.6071.99 7.7471.74 0.68
b2-microglobulin clearance (l/treatment) 1.1270.41 1.1070.37 0.78
Sodium removal (mmol/treatment) 176.4777.7 128.0777.8 0.010
Peritoneal ultrafiltration (ml/treatment) 2051.17683.5 2215.67598.2 0.10
Glucose absorption (g/treatment) 159.5729.2 189.4774.1 0.046
Protein loss (g/treatment) 4.9571.40 4.3771.71 0.17
APD, automated peritoneal dialysis.
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Adverse events
Adverse events in the 18 APD patients included in the final
analysis were hypokalemia (n¼ 1) and hypotension (n¼ 1),
which required an increase of oral fluid intake and reduction
of antihypertensive agents. Both events occurred during
‘high-flow’ treatment. One patient complained of moderate
abdominal distension during both study weeks. This patient
had only a daytime fill volume of 1 l before the start of the
trial. Including the patient with severe abdominal distension
during ‘manual exchange’ treatment and the patient with
diarrhea and hypotension during ‘high-flow’ treatment, who
both dropped out, there was no remarkable difference in the
number of adverse events between the two APD regimens.
DISCUSSION
Until now, it remains unclear whether addition of manual
daytime exchanges or increasing the dialysate flow during
night time is the best strategy to optimize APD treatment.
Durand et al.5 described that the diffusion of uremic toxins
through the peritoneal membrane resembles a parabola with
a maximal point. If dialysate flow is increased above this
point, clearances may not increase further or may even
decrease, as the time spent for inflow and outflow becomes a
significant part of the entire treatment period, which is less
effective for diffusion. Although these data are important,
they are only based on six patients. Therefore, a final
conclusion is not available based on these results. Accord-
ingly, the maximal effective dialysate flow for small solute
clearances differs between several clinical studies. In non-
randomized trials, increases in dialysate flow from 1.1 and
1.7 l/h to 2 and 3 l/h have been reported to improve small
solute clearances in APD patients.3,4 In contrast, Amici et al.6
found significantly higher Kt/V values but unchanged
creatinine clearances in patients with 9-h continuous tidal
peritoneal dialysis (including two daytime dwells) after
elevating the cycler treatment volume from 17 to 22, 27,
and 32 l. Based on kinetic modeling, Blake et al.7 showed that
in continuous cyclic peritoneal dialysis patients with a cycler
treatment volume of 15 l, addition of a manual daytime
exchange is superior to further increases in nightly dialysate
volumes. Despite a non-inferiority design in the present
randomized controlled clinical trial, we found significantly
higher peritoneal creatinine and urea clearances when using a
high dialysate flow as compared to a conventional low-flow
treatment regimen with one manual daytime exchange. Inclu-
ding only patients with a body surface area of 1.7–2.0 m2
in the analysis yielded consistent results. A sub-analysis
of LA and HA transporters showed that this effect on clearances
was most marked in the latter patient group, but smaller
and not significant in LA transporters. In contrast to
peritoneal creatinine clearance, phosphate clearance did not
significantly differ between the two treatments in the entire
patient group nor in the subgroups of LA and HA
transporters. This is in contrast to findings of Sedlacek
et al.,8 who found a strong relationship between creatinine
and phosphate clearance in both continuous ambulatory
peritoneal dialysis and continuous cyclic peritoneal dialysis
patients. However, in a recent trial, improvement of
clearances in APD was markedly less for phosphate than
for creatinine when nightly treatment volume was increased
by 71%.9 Further studies are needed to find an explanation
for these conflicting findings.
Although peritoneal small solute clearances are associated
with patient survival in some studies,10,11 they have no
influence on mortality in other recent trials.12,13 This points
to the impact of other factors contributing to clinical
outcome in peritoneal dialysis (PD) patients. Most impor-
tantly, there is a question as to whether the price for
improving small solute clearances by high dialysate flow may
be a decreased removal of larger uremic toxins and sodium.
Because of their high molecular weight, middle molecules
and small proteins need longer dwell times to diffuse from
peritoneal capillaries into the peritoneal cavity. Equilibrium
between blood and dialysate is not reached for these toxins
even after a dwell time of more than 10 h. Keshaviah14
showed that middle molecular clearances in continuous
ambulatory peritoneal dialysis patients are only marginally
influenced by the number of dialysate exchanges. Accord-
ingly, it can be expected that the addition of one or more
manual daytime exchanges in continuous cyclic peritoneal
dialysis patients instead of a long daytime dwell will
not largely improve removal of these substances. However,
these data are based on computer modeling, not on
actual clearance measurements. In contrast to the number
of manual dialysate exchanges, the overall contact time
between peritoneal membrane and dialysate may have a more
important influence on diffusion of larger molecules.
Based on the concept of Durand et al.,5 the maximal
effective dialysate flow of middle molecules is reached earlier
than for small solutes, possibly leading to a decrease of
clearances of these toxins with high nightly dialysate
treatment volumes. Data in patients treated by intermittent
APD, however, are controversial, showing a decrease of
vitamin B12 clearances after elevating the dialysate flow from
2 to 4 l/h15 as well as no influence of dialysate flow on
b2-microglobulin clearances.
3 In our trial, both continuous
APD treatments (‘manual exchange’ and ‘high flow’) were
equivalent with respect to b2-microglobulin clearances,
even in LA transporters. b2-Microglobulin clearances found
in the present study were twice as high as in our previous
study on intermittent cycler therapy,3 confirming that it is
not dialysate flow or number of manual exchanges but
continuous contact of the peritoneum with dialysate that is
Table 3 | Comparison of treatment costs (only including
dialysis solutions and tubing)
Body surface
area (m2)
‘Manual exchange’
treatment
(h per year)
‘High flow’
treatment
(h per year)
Increase in
costs (%)
o1.7 31 000.3 41 625.5 34.3
1.7–2.0 31 000.3 48 184.7 55.4
42 34 334.5 54 744.0 59.4
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the most important determinant of b2-microglobulin re-
moval in APD patients.
In prospective cohort studies, both sodium and fluid
removal were identified as independent predictors of survival
in PD patients.2,16 Sodium removal in APD is lower as
compared to continuous ambulatory peritoneal dialysis
patients because of sodium sieving at the peritoneal mem-
brane, which occurs during short dwell times.17–20 Our finding
of significantly higher sodium removal in ‘manual exchange’ as
compared to ‘high flow’ treatment is in agreement with a
cross-sectional study that has reported that, after controlling
for ultrafiltration, inclusion of a daytime exchange and longer
dwell times were independent predictors of improved
peritoneal sodium elimination.19 Furthermore, sodium sieving
during ‘high flow’ treatment becomes most marked in patients
with LA transport rates. In contrast to sodium removal,
peritoneal ultrafiltration in the present study was slightly but
not significantly increased with high dialysate flow.
We calculated only peritoneal glucose absorption, which
was higher with increasing dialysate flow. However, because
of its longer daytime dwell during ‘high flow’ treatment,
carbohydrate absorption derived from icodextrin may be
additionally greater than after ‘manual exchange’ treatment,
most likely increasing the difference in caloric load between
the two APD regimens.
Peritoneal protein loss during PD is significant and may
contribute to malnutrition in these patients.21 We observed
no difference in protein loss between ‘high-flow’ treatment
and the ‘manual exchange’ treatment in our study. This
finding extends observations by Twardowski et al.,22 Perez
et al.,4 and also by our own group3 showing that not only
during intermittent APD but also with continuous cycler
treatment, increase of dialysate flow has no influence on
peritoneal protein loss.
What are the practical consequences of our study? The
lack of necessity of manual daytime exchanges may have
several advantages. The first and most apparent advantage is
the improvement of quality of life, as manual exchanges
decrease daytime flexibility and may be even more proble-
matic for PD patients who work or who require assistance
from another person. Secondly, the peritonitis risk increases
with the number of manual dialysate exchanges.23 Therefore,
a ‘high-flow’ regimen as performed in this study may
decrease the risk of infection as compared to APD treatment
modalities including manual daytime exchanges. However,
data on infection rates between APD patients and continuous
ambulatory peritoneal dialysis patients, who also perform
more connections/disconnections at the catheter, are con-
troversial.24,25
Particularly in LA patients, possible advantages of
increased small solute clearances during ‘high-flow’ treat-
ment may be eclipsed by the significant decrease in sodium
removal, which independently of ultrafiltration influences
clinical outcome. Furthermore, the higher cost of high-flow
APD may hinder a more liberal application of this treatment
modality.
The contact of the peritoneal membrane with larger
amounts of fresh dialysate when changing from the
conventional to the ‘high-flow’ regimen may be another
point of concern. Although clinical consequences are
discussed controversially,26,27 the use of more biocompatible
solutions is recommended in this situation.
In conclusion, small solute clearances can be significantly
improved and middle molecule clearances maintained in
APD patients by increasing the nightly dialysate flow instead
of adding a manual daytime exchange. However, the possible
benefit of better small solute clearances with higher nightly
treatment volumes has to be weighed against increased costs
and the possible negative impact of impaired sodium
removal. These latter aspects have to be especially considered
in LA patients in whom the difference in clearances was
smaller but in whom sodium sieving was more marked
during ‘high-flow’ treatment than in HA patients.
MATERIALS AND METHODS
Participants
This open-label randomized controlled crossover trial was per-
formed at the Medical University of Vienna. We included patients
older than 18 years and in a clinically stable condition who were
treated with APD for at least 3 months. None of the patients had
experienced an episode of peritonitis within 2 months before the
study began. Only patients with average peritoneal transport rates
(HA or LA) were included. Exclusion criteria were participation in
another study within 3 weeks before the study began, allergy to
icodextrin, acute impairment of general condition, and severe
chronic heart failure (class NYHA III or IV). The Ethical Review
Board at the University of Vienna approved the study. All patients
gave written informed consent.
Study design
The study period lasted 3 weeks. All patients sequentially underwent
two different continuous APD regimens (‘manual exchange’
treatment and ‘high-flow’ treatment) for 7 days each (week 1 and
week 3) with an intermittent washout period of 7 days. ‘Manual
exchange’ treatment represents a conventional APD therapy with
low nightly dialysate flow and one manual daytime exchange (two
daytime dwells) (Figure 1). ‘High-flow’ treatment represents cycler
therapy with high dialysate flow and without manual daytime
exchange (one daytime dwell) (Figure 1). As the optimal treatment
and fill volume depend on body size and body weight, dialysate
volumes were adapted on body surface area. However, most patients
(n¼ 12) had a body surface area of 1.7–2 m2. Body surface area was
42 m2 in three patients and o1.7 m2 in three patients, respectively
(Table 1). A tidal mode was used in all patients. This was not to
improve clearances, as several studies have shown that tidal
peritoneal dialysis does not increase removal of small solutes or
middle molecules as compared to conventional APD when dialysate
flow is kept constant.3,28,29 The reason for choosing tidal peritoneal
dialysis was to minimize outflow alarms and, more importantly,
mechanical outflow problems, especially during the days when
clearances were measured. However, a rather high tidal volume of
75% was used uniformly in both study weeks.
During ‘manual exchange’ treatment, icodextrin (Extraneal,
Baxter Healthcare Corp., Norfolk, UK) was used for one of the
two daytime dwells (10 h), whereas the other daytime dwell (5 h)
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was performed with conventional glucose solution (Dianeal, Baxter
Healthcare Corp., Norfolk, UK). During ‘high-flow’ treatment, there
was only one daytime dwell (15 h, no manual exchange). Icodextrin
solution was used for this dwell. During the first 5 days of both
study weeks (weeks 1 and 3), the dialysate glucose concentration was
adapted according to the need of each patient (dependent on
residual renal function and peritoneal ultrafiltration). However,
during the last 2 days of weeks 1 and 3 (blood and dialysate
sampling), all patients used exclusively 2.27% glucose solutions
(except for the one daytime dwell, which was performed with
icodextrin). Patients were asked to adapt their fluid intake according
to the changed peritoneal ultrafiltration on these 4 days. During the
washout period (second week), each patient performed her/his
regular APD treatment. All treatment sessions were performed using
a Home Choice PRO-cycler (Baxter Healthcare Corporation,
McGaw Park, IL, USA). Patient compliance was verified by analyzing
the computer card of the cycler on which all treatments were
recorded.
Measurements
Measurement of clearances, peritoneal ultrafiltration, and protein
loss were performed during the last 2 days of each study week (days
6 and 7, days 20 and 21). On these days, patients were asked to
collect the entire effluent of each cycler session (including the initial
drain volume) and, during ‘manual exchange’ treatment, addition-
ally the effluent obtained during the manual daytime exchange.
Dialysate samples were taken from these dialysate effluents. A single
blood sample was also taken on each of these 4 days (in the middle
of the daytime dwell, usually at 1400–1600 hours). Peritoneal
clearances, protein loss, peritoneal ultrafiltration, and glucose
absorption were calculated as reported previously.3 As each patient
was her/his own control, clearances were not normalized to body
surface area. Renal clearances were not measured. Plasma and
dialysate sodium were determined by an indirect electrode method
after pre-dilution of the sample. This method has shown a good
correlation with measurements performed by the flame photometry
technique.30 Sodium removal was calculated as difference between
sodium concentration in the drained dialysate total drain volume
and sodium concentration in the volume of instilled dialysate total
inflow volume, as reported previously.18,20
To characterize peritoneal transport types, we used the D/P of
creatinine, calculated during the peritoneal equilibration test at 4 h
before the start of the study.31,32 Patients with a D/P of creatinine
between 0.50 and 0.64 at 4 h were defined as LA transporters,
whereas those with a D/P of creatinine between 0.65 and 0.81 at 4 h
were categorized as HA transporters.
Biochemical analyses were performed in an ISO 9001 certified
laboratory. The correct entry of the data in the case report forms and
in the electronic database was assured by double-checking by study
monitors.
Study hypothesis and outcomes
We hypothesized that two different APD regimens (‘manual
exchange’ treatment and ‘high-flow’ treatment) would perform
equally with respect to clearance capacity.
The primary study end point was the difference in 24 h
peritoneal small solute clearance, both creatinine and urea, between
‘manual exchange’ treatment and ‘high-flow’ treatment. Secondary
end points were changes in 24 h phosphate and b2-microglobulin
clearances, sodium removal, ultrafiltrate volume, peritoneal glucose
absorption, and protein loss between the two treatments.
Sample size
As intensified APD is especially important for patients with low
residual renal function, it was determined that peritoneal creatinine
clearance be 7.5–8.5 l/treatment, corresponding to a weekly clearance
of 50–60 l. The defined a level was 5% (P¼ 0.05) with a minimum
power of 80% (b¼ 0.80). A difference of 10% in the means was
defined as clinically relevant based on previous data, which
demonstrated an increased risk for mortality with a decline of
5 l/week/1.73 m2 peritoneal creatinine clearance.10 The s.d. of
creatinine measurements was estimated between 10 and 12%. A
sample size between 16 and 23 patients was determined as necessary
to demonstrate equivalence between the two APD regimens
using a crossover design based on the assumptions made above.
Sample size calculations were performed using the software ‘Sample
Size V2.0’.
Randomization
Patients were randomized for the sequence of the two treatments
(‘manual exchange’ treatment in week 1 followed by ‘high-flow’
treatment in week 3 or vice versa) by computer-generated random
digits (software package Sample Size V2.0) using sealed opaque
envelopes. These envelopes were opened for each patient immedi-
ately before the study began. Patients were enrolled by one of the
investigators. Randomization was performed by an independent
investigator not involved in patient care.
Statistical methods
Continuous variables are presented as the mean and s.d. Continuous
variables derived from the measurement of clearance parameters,
ultrafiltration, sodium removal, glucose absorption, and protein loss
were repeated two times on two sequential days (days 6, 7 and days
20, 21), and average values from these measurements were taken for
final statistical analysis. Percentages were calculated for dichoto-
mous variables. All calculations address paired within-subject
comparisons of ‘manual exchange’ vs ‘high-flow’ regimens. There-
fore, continuous variables were compared by paired t-tests. Data
were checked for a normal distribution and all comparisons were
recalculated with non-parametric statistical methods (Wilcoxon
paired tests). In cases of divergent results between parametric and
non-parametric methods, the more conservative P-value was
presented.
Calculations were performed using SPSS for Windows (Version
12.0, SPSS Inc., Chicago, IL, USA) and Stata release 8.0 (Stata Corp.,
College Station, TX, USA).
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